Overview

A Study of ANAVEX3-71 in Adults With Schizophrenia

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.
Phase:
PHASE2
Details
Lead Sponsor:
Anavex Life Sciences Corp.
Collaborators:
COGNISION
Cognitive Research Corporation
Hassman Research Institute